Focused On-demand Library for L-seryl-tRNA(Sec) kinase

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q8IV42

UPID:

PSTK_HUMAN

Alternative names:

O-phosphoseryl-tRNA(Sec) kinase

Alternative UPACC:

Q8IV42; Q6ZSS9

Background:

L-seryl-tRNA(Sec) kinase, also known as O-phosphoseryl-tRNA(Sec) kinase, plays a pivotal role in the biosynthesis of selenocysteine by specifically phosphorylating seryl-tRNA(Sec) to O-phosphoseryl-tRNA(Sec). This process is an essential step in the synthesis of selenoproteins, which are crucial for various cellular functions including antioxidant defense and redox regulation.

Therapeutic significance:

Understanding the role of L-seryl-tRNA(Sec) kinase could open doors to potential therapeutic strategies. Its critical function in selenoprotein synthesis suggests that modulation of this kinase's activity could influence cellular protection mechanisms against oxidative stress, offering avenues for intervention in diseases where oxidative damage is a key factor.